Study of a new drug for dup15q syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests an investigational medication for children and teenagers with dup15q syndrome, a genetic condition that can cause developmental delays and other challenges. The study aims to see if the drug is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 14 years old.
- You must have a confirmed diagnosis of dup15q syndrome with a specific genetic change (duplication or triplication of the 15q11.2-q13.1 region).
- Your symptoms must be at least mildly impairing, as rated by a doctor on a standard scale.
- If you have a type of dup15q with an extra isodicentric chromosome, you must not have a history of seizures (epilepsy).
- If you have the other type (interstitial), any seizures you have must be well-controlled — no rescue medicine more than once a month, no status epilepticus in the past 6 months, and no more than four anti-seizure drugs.
- You must not have changed any medications in the past 6–8 weeks, and no changes to behavioral therapies in the past 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine (all-trans retinoic acid) for children with autism who also have a specific genetic change (15q11-13 duplication). The goal is to see if it can help with autism symptoms.
This early trial tests whether dupilumab can reduce itching in people with certain inherited (genetic) inflammatory skin conditions. It may help by calming skin inflammation that causes ongoing itch and sleep problems.
This study follows people with a rare genetic condition called 7q11.23 microduplication over time to understand how it affects development, learning, and health. Participants will have interviews, thinking and memory tests, and an MRI brain scan.
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
This trial tests an experimental medicine called ION440 for people with MECP2 Duplication Syndrome. The medicine is given as an injection into the spinal fluid, and the study aims to check its safety and how well it works.
This trial tests a new CRISPR therapy that edits RNA to treat a rare genetic condition called MECP2 duplication syndrome (MDS). It is for boys aged 2 to 18 who have stable seizures and no other major health problems, with the goal of improving symptoms and safety.
Hear when a new Dup15q Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.